BI 443651

Drug Profile

BI 443651

Alternative Names: BI443651

Latest Information Update: 11 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antifibrotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 21 Feb 2018 Boehringer Ingelheim completes a phase-I clinical trials in Asthma in United Kingdom (Inhalation) (NCT03135899)
  • 18 May 2017 Phase-I clinical trials in Asthma in United Kingdom (Inhalation) (NCT03135899)
  • 05 May 2017 Boehringer Ingelheim plans a phase I trial for Asthma (NCT03135899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top